glp-1 and vertigo The Risk of Vestibular Disorders with Semaglutide Tirzepatide: Findings from a Large Real-World Cohort Dizziness and Wegovy: What's the

A shift in focus from weight loss to health gain reduces stigma for patients living with obesity

Abstract The advent of incretin mimetics such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) has enriched the armamentarium for diabetes management owing to their glycaemic as well as extra-glycaemic benefits

Do I have to try diet and exercise before getting the injections

Blood pressure and heart rate monitoring Cardiovascular monitoring remains paramount for GLP-1 non-responders transitioning to sympathomimetic agents like phentermine

Wegovy (semaglutide) is a once-weekly injectable medication licensed in the UK for chronic weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity

With this knowledge, studies are being conducted to determine the effects of existing GLP-1 drugs for diabetes on the central nervous system